NCT00580957 is a NA clinical trial of Blocked in Obesity, sponsored by Vanderbilt University.

Who is sponsoring NCT00580957?

NCT00580957 is sponsored by Vanderbilt University.

What drugs are being tested in NCT00580957?

Interventions in NCT00580957: Blocked, Intact.

Is NCT00580957 still recruiting?

NCT00580957 is currently completed. Last updated 6 July 2016.

Are results published for NCT00580957?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2016-07-06 · How we verify

NCT00580957

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Autonomic Nervous System and the Metabolic Syndrome

Completed NA Results posted Last updated 6 July 2016

What this trial tests

NA trial testing Blocked in Obesity in 56 participants. Completed in 1 May 2015.

Timeline

1 August 2008

Primary endpoint
1 May 2015

1 May 2015

Quick facts

Lead sponsor	Vanderbilt University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Enrollment	56
Start date	1 August 2008
Primary completion	1 May 2015
Estimated completion	1 May 2015
Sites	1 location across United States

Drugs / interventions tested

Blocked — full drug profile →
Intact — full drug profile →

Conditions studied

Obesity — all drugs for Obesity →

Sponsor

Vanderbilt University

Who can join

Adults 18 to 60, any sex, with Obesity. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Insulin Resistance
Time frame: Last 30 minutes of a two hour insulin clamp
Glucose infusion rate in mg/kg/min

Sponsor's own description

The overall goal of this proposal is to determine the role of the autonomic nervous system in the insulin resistant state associated with obesity and the metabolic syndrome. Obesity results from an accumulation of excessive fat deposit due to increase caloric intake or decrease energy expenditure, this condition is usually associated with diseases such as hypertension or diabetes, a cluster known as the metabolic syndrome. The first step in the development of the metabolic syndrome is a resistance to the action of insulin. The mechanism underlying insulin resistance in obesity is still unknown, however some investigators have proposed that the autonomic nervous system, particularly the increase sympathetic activation in obesity may play an important role. We have extensive experience studying the role of the autonomic nervous system in the cardiovascular alterations associated with obesity by producing complete autonomic withdrawal with a drug named trimethaphan. We propose to use the same approach to study the role of the autonomic nervous system in the development of insulin resistance in obesity.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Autonomic blockade improves insulin sensitivity in obese subjects.
Gamboa A, Okamoto LE, Arnold AC, Figueroa RA, et al · · 2014 · cited 40× · PMID 25001269 · DOI 10.1161/hypertensionaha.114.03738

Verify or expand the search:

Other recruiting trials for Obesity

Currently open trials in the same condition.

NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting
NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee · Phase 3 · recruiting
NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07481630 — A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoart · Phase 3 · recruiting
NCT07527195 — Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscl · Phase 1 · recruiting

Other Vanderbilt University trials

Trials by the same sponsor.

NCT06598579 — Evaluation of MBCT Implemented in Vietnamese Buddhist Pagoda · NA · not yet recruiting
NCT06482944 — Whole Food for Families: A Pilot RCT of a Dietary Guidelines-Based Intervention to Prevent Type 2 Diabetes · NA · recruiting
NCT07220746 — Understanding Cognitive-Academic Bidirectionality in Math Learning Disabilities · NA · recruiting
NCT06464497 — Whole Foods for Teens: A Pilot Dietary Intervention to Reduce Body Adiposity in Adolescents With Obesity · NA · recruiting
NCT05472961 — Eye Movements in Visual Search · NA · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00580957 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Vanderbilt University
Last refreshed: 6 July 2016

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00580957.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing